Cargando…
The evaluation of ADME and pharmacokinetic properties of decoquinate derivatives for the treatment of malaria
The emergence of Plasmodium falciparum (Pf) parasite strains tolerant of the artemisinin component and resistant to the other drug component in artemisinin combination therapies (ACTs) used for treatment now markedly complicates malaria control. Thus, development of new combination therapies are urg...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450014/ https://www.ncbi.nlm.nih.gov/pubmed/36091789 http://dx.doi.org/10.3389/fphar.2022.957690 |
_version_ | 1784784431365488640 |
---|---|
author | Watson, Daniel J. Laing, Lizahn Beteck, Richard M. Gibhard, Liezl Haynes, Richard K. Wiesner, Lubbe |
author_facet | Watson, Daniel J. Laing, Lizahn Beteck, Richard M. Gibhard, Liezl Haynes, Richard K. Wiesner, Lubbe |
author_sort | Watson, Daniel J. |
collection | PubMed |
description | The emergence of Plasmodium falciparum (Pf) parasite strains tolerant of the artemisinin component and resistant to the other drug component in artemisinin combination therapies (ACTs) used for treatment now markedly complicates malaria control. Thus, development of new combination therapies are urgently required. For the non-artemisinin component, the quinolone ester decoquinate (DQ) that possesses potent activities against blood stage Pf and acts on a distinct target, namely the Pf cytochrome bc (1) complex, was first considered. However, DQ has poor drug properties including high lipophilicity and exceedingly poor aqueous solubility (0.06 μg/ml), rendering it difficult to administer. Thus, DQ was chemically modified to provide the secondary amide derivative RMB005 and the quinoline O-carbamate derivatives RMB059 and RMB060. The last possesses sub-nanomolar activities against multidrug resistant blood stages of Pf, and P. berghei sporozoite liver stages. Here we present the results of ADME analyses in vitro and pharmacokinetic analyses using C57BL/6 mice. The amide RMB005 had a maximum mean whole blood concentration of 0.49 ± 0.02 µM following oral administration; however, the area under the curve (AUC), elimination half-life (t(1/2)) and bioavailability (BA) were not significantly better than those of DQ. Surprisingly, the quinoline O-carbamates which can be recrystallized without decomposition were rapidly converted into DQ in human plasma and blood samples. The maximum concentrations of DQ reached after oral administration of RMB059 and RMB060 were 0.23 ± 0.05 and 0.11 ± 0.01 µM, the DQ elimination half-lives were 4.79 ± 1.66 and 4.66 ± 1.16 h, and the DQ clearance were 19.40 ± 3.14 and 21.50 ± 3.38 respectively. Under these assay conditions, the BA of DQ could not be calculated Overall although RMB059 and -060 are labile in physiological medium with respect to the DQ parent, the potential to apply these as prodrugs is apparent from the current data coupled with their ease of preparation. |
format | Online Article Text |
id | pubmed-9450014 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94500142022-09-08 The evaluation of ADME and pharmacokinetic properties of decoquinate derivatives for the treatment of malaria Watson, Daniel J. Laing, Lizahn Beteck, Richard M. Gibhard, Liezl Haynes, Richard K. Wiesner, Lubbe Front Pharmacol Pharmacology The emergence of Plasmodium falciparum (Pf) parasite strains tolerant of the artemisinin component and resistant to the other drug component in artemisinin combination therapies (ACTs) used for treatment now markedly complicates malaria control. Thus, development of new combination therapies are urgently required. For the non-artemisinin component, the quinolone ester decoquinate (DQ) that possesses potent activities against blood stage Pf and acts on a distinct target, namely the Pf cytochrome bc (1) complex, was first considered. However, DQ has poor drug properties including high lipophilicity and exceedingly poor aqueous solubility (0.06 μg/ml), rendering it difficult to administer. Thus, DQ was chemically modified to provide the secondary amide derivative RMB005 and the quinoline O-carbamate derivatives RMB059 and RMB060. The last possesses sub-nanomolar activities against multidrug resistant blood stages of Pf, and P. berghei sporozoite liver stages. Here we present the results of ADME analyses in vitro and pharmacokinetic analyses using C57BL/6 mice. The amide RMB005 had a maximum mean whole blood concentration of 0.49 ± 0.02 µM following oral administration; however, the area under the curve (AUC), elimination half-life (t(1/2)) and bioavailability (BA) were not significantly better than those of DQ. Surprisingly, the quinoline O-carbamates which can be recrystallized without decomposition were rapidly converted into DQ in human plasma and blood samples. The maximum concentrations of DQ reached after oral administration of RMB059 and RMB060 were 0.23 ± 0.05 and 0.11 ± 0.01 µM, the DQ elimination half-lives were 4.79 ± 1.66 and 4.66 ± 1.16 h, and the DQ clearance were 19.40 ± 3.14 and 21.50 ± 3.38 respectively. Under these assay conditions, the BA of DQ could not be calculated Overall although RMB059 and -060 are labile in physiological medium with respect to the DQ parent, the potential to apply these as prodrugs is apparent from the current data coupled with their ease of preparation. Frontiers Media S.A. 2022-08-19 /pmc/articles/PMC9450014/ /pubmed/36091789 http://dx.doi.org/10.3389/fphar.2022.957690 Text en Copyright © 2022 Watson, Laing, Beteck, Gibhard, Haynes and Wiesner. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Watson, Daniel J. Laing, Lizahn Beteck, Richard M. Gibhard, Liezl Haynes, Richard K. Wiesner, Lubbe The evaluation of ADME and pharmacokinetic properties of decoquinate derivatives for the treatment of malaria |
title | The evaluation of ADME and pharmacokinetic properties of decoquinate derivatives for the treatment of malaria |
title_full | The evaluation of ADME and pharmacokinetic properties of decoquinate derivatives for the treatment of malaria |
title_fullStr | The evaluation of ADME and pharmacokinetic properties of decoquinate derivatives for the treatment of malaria |
title_full_unstemmed | The evaluation of ADME and pharmacokinetic properties of decoquinate derivatives for the treatment of malaria |
title_short | The evaluation of ADME and pharmacokinetic properties of decoquinate derivatives for the treatment of malaria |
title_sort | evaluation of adme and pharmacokinetic properties of decoquinate derivatives for the treatment of malaria |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450014/ https://www.ncbi.nlm.nih.gov/pubmed/36091789 http://dx.doi.org/10.3389/fphar.2022.957690 |
work_keys_str_mv | AT watsondanielj theevaluationofadmeandpharmacokineticpropertiesofdecoquinatederivativesforthetreatmentofmalaria AT lainglizahn theevaluationofadmeandpharmacokineticpropertiesofdecoquinatederivativesforthetreatmentofmalaria AT beteckrichardm theevaluationofadmeandpharmacokineticpropertiesofdecoquinatederivativesforthetreatmentofmalaria AT gibhardliezl theevaluationofadmeandpharmacokineticpropertiesofdecoquinatederivativesforthetreatmentofmalaria AT haynesrichardk theevaluationofadmeandpharmacokineticpropertiesofdecoquinatederivativesforthetreatmentofmalaria AT wiesnerlubbe theevaluationofadmeandpharmacokineticpropertiesofdecoquinatederivativesforthetreatmentofmalaria AT watsondanielj evaluationofadmeandpharmacokineticpropertiesofdecoquinatederivativesforthetreatmentofmalaria AT lainglizahn evaluationofadmeandpharmacokineticpropertiesofdecoquinatederivativesforthetreatmentofmalaria AT beteckrichardm evaluationofadmeandpharmacokineticpropertiesofdecoquinatederivativesforthetreatmentofmalaria AT gibhardliezl evaluationofadmeandpharmacokineticpropertiesofdecoquinatederivativesforthetreatmentofmalaria AT haynesrichardk evaluationofadmeandpharmacokineticpropertiesofdecoquinatederivativesforthetreatmentofmalaria AT wiesnerlubbe evaluationofadmeandpharmacokineticpropertiesofdecoquinatederivativesforthetreatmentofmalaria |